Oric Pharmaceuticals, Inc. ORIC
We take great care to ensure that the data presented and summarized in this overview for Oric Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ORIC
View all-
Nextech Invest, Ltd. Zurich, V87.16MShares$93.8 Million13.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$88.1 Million6.03% of portfolio
-
Vr Adviser, LLC New York, NY6.6MShares$86.4 Million11.96% of portfolio
-
Viking Global Investors LP6.57MShares$86 Million0.22% of portfolio
-
Nextech Invest Ag5.29MShares$69.2 Million7.95% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$63.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.65MShares$60.9 Million0.0% of portfolio
-
Sr One Capital Management, LP4.51MShares$59.1 Million12.39% of portfolio
-
Alkeon Capital Management LLC New York, NY4.5MShares$59 Million0.08% of portfolio
-
Nea Management Company, LLC Timonium, MD4.12MShares$53.9 Million3.07% of portfolio
Latest Institutional Activity in ORIC
Top Purchases
Top Sells
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Insider Transactions at ORIC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2025
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,720
-13.59%
|
$96,480
$9.06 P/Share
|
|
Dec 16
2025
|
Pratik S Multani Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,720
-13.59%
|
$96,480
$9.06 P/Share
|
|
Dec 16
2025
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
33,374
-5.43%
|
$300,366
$9.06 P/Share
|
|
Dec 15
2025
|
Dominic Piscitelli Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,333
+27.11%
|
-
|
|
Dec 15
2025
|
Pratik S Multani Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,333
+27.11%
|
-
|
|
Dec 15
2025
|
Jacob Chacko PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
83,666
+11.97%
|
-
|
|
Dec 08
2025
|
Lori Anne Kunkel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.62%
|
$70,000
$7.9 P/Share
|
|
Dec 04
2025
|
Lori Anne Kunkel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,534
+6.94%
|
$16,602
$3.75 P/Share
|
|
Oct 06
2025
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
37,461
-6.59%
|
$449,532
$12.32 P/Share
|
|
Oct 06
2025
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,000
-18.54%
|
$154,000
$14.52 P/Share
|
|
Oct 06
2025
|
Dominic Piscitelli Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+15.64%
|
$44,000
$4.36 P/Share
|
|
Oct 03
2025
|
Richard A. Heyman |
BUY
Exercise of conversion of derivative security
|
Direct |
32,800
+22.39%
|
$65,600
$2.68 P/Share
|
|
Oct 01
2025
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
53,001
-8.52%
|
$636,012
$12.05 P/Share
|
|
Sep 30
2025
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
34,538
-5.26%
|
$414,456
$12.01 P/Share
|
|
Sep 22
2025
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
125,000
-16.0%
|
$1,250,000
$10.8 P/Share
|
|
Jul 01
2025
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-29.28%
|
$200,000
$10.05 P/Share
|
|
Jun 24
2025
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,466
-32.21%
|
$324,660
$10.5 P/Share
|
|
Jun 23
2025
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,034
-0.51%
|
$10,340
$10.01 P/Share
|
|
Jun 23
2025
|
Angie You |
BUY
Open market or private purchase
|
Direct |
1,403
+4.77%
|
$12,627
$9.43 P/Share
|
|
Jun 20
2025
|
Angie You |
BUY
Open market or private purchase
|
Direct |
26,597
+50.0%
|
$239,373
$9.39 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 250K shares |
|---|---|
| Open market or private purchase | 28K shares |
| Open market or private sale | 376K shares |
|---|